@entity1140 and @entity3446 induce XXXX in female @entity35 .

@entity1 @entity3610 @entity6 @entity3446 @entity42 @entity854 @entity1140 @entity35 @entity11636 @entity4854 @entity413
BACKGROUND: Immunosuppression medications contribute to posttransplant @entity6 in @entity1 and can cause insulin resistance in male @entity35 . @entity1140 ( @entity11636 )- @entity3446 (SIR) immunosuppression is also associated with appearance of @entity42 in transplant @entity1 . Because insulin resistance is observed in @entity1 with @entity3610 , we hypothesized that @entity11636 or SIR may induce @entity854 . METHODS: We monitored estrus cycles of adult female @entity35 treated daily with @entity11636 , SIR, and combination of @entity11636 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity413 to determine their @entity413 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity11636 and @entity11636 -SIR treatments increased mean random @entity413 concentrations (P<0.05). @entity11636 , SIR, and @entity11636 -SIR treatments also increased the @entity413 response to oral @entity413 challenge (P<0.05). The insulin response to @entity413 was significantly higher in @entity35 treated with SIR compared with @entity11636 (P<0.05). @entity11636 , SIR and @entity11636 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity11636 -SIR treatment compared with controls. The @entity11636 and @entity11636 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity11636 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity4854 , both @entity11636 and SIR induced @entity854 in adult female @entity35 , likely through different mechanisms.
